NASDAQ:JNCE - Jounce Therapeutics News Headlines

$4.13
-0.08 (-1.90 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
$4.10
Now: $4.13
$4.29
50-Day Range
$4.18
MA: $4.55
$5.02
52-Week Range
$2.66
Now: $4.13
$8.58
Volume47,619 shs
Average Volume181,479 shs
Market Capitalization$136.17 million
P/E RatioN/A
Dividend YieldN/A
Beta3.45

Headlines

Jounce Therapeutics (NASDAQ JNCE) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Jounce Therapeutics Inc (NASDAQ:JNCE) Will Post Earnings of -$0.31 Per ShareZacks: Analysts Anticipate Jounce Therapeutics Inc (NASDAQ:JNCE) Will Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - July 18 at 6:17 PM
Is Jounce Therapeutics, Inc. (JNCE) A Good Stock To Buy?Is Jounce Therapeutics, Inc. (JNCE) A Good Stock To Buy?
finance.yahoo.com - June 30 at 9:20 AM
Jounce Therapeutics Inc (NASDAQ:JNCE) Short Interest Down 9.8% in JuneJounce Therapeutics Inc (NASDAQ:JNCE) Short Interest Down 9.8% in June
www.americanbankingnews.com - June 28 at 10:27 PM
$14.51 Million in Sales Expected for Jounce Therapeutics Inc (NASDAQ:JNCE) This Quarter$14.51 Million in Sales Expected for Jounce Therapeutics Inc (NASDAQ:JNCE) This Quarter
www.americanbankingnews.com - June 27 at 1:46 AM
Zacks: Brokerages Expect Jounce Therapeutics Inc (NASDAQ:JNCE) to Announce -$0.31 Earnings Per ShareZacks: Brokerages Expect Jounce Therapeutics Inc (NASDAQ:JNCE) to Announce -$0.31 Earnings Per Share
www.americanbankingnews.com - June 25 at 8:27 PM
Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial CancerJounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
finance.yahoo.com - June 18 at 6:43 PM
An In-Depth Look At Jounce TherapeuticsAn In-Depth Look At Jounce Therapeutics
seekingalpha.com - June 17 at 5:42 PM
Jounce Therapeutics to Present at Upcoming Investor Conferences in JuneJounce Therapeutics to Present at Upcoming Investor Conferences in June
finance.yahoo.com - June 11 at 10:35 AM
Estimating The Intrinsic Value Of Jounce Therapeutics, Inc. (NASDAQ:JNCE)Estimating The Intrinsic Value Of Jounce Therapeutics, Inc. (NASDAQ:JNCE)
finance.yahoo.com - May 23 at 10:28 AM
Jounce Therapeutics, Inc. (JNCE) CEO Dr. Rich Murray on Q1 2019 Results - Earnings Call TranscriptJounce Therapeutics, Inc. (JNCE) CEO Dr. Rich Murray on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 10:42 AM
Edited Transcript of JNCE.O earnings conference call or presentation 8-May-19 12:00pm GMTEdited Transcript of JNCE.O earnings conference call or presentation 8-May-19 12:00pm GMT
finance.yahoo.com - May 9 at 10:40 AM
Jounce Therapeutics Q1 top line off 2%Jounce Therapeutics Q1 top line off 2%
seekingalpha.com - May 8 at 10:32 AM
Jounce Therapeutics Reports First Quarter 2019 Financial ResultsJounce Therapeutics Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 8 at 10:32 AM
Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue EstimatesJounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 8 at 10:32 AM
Will Jounce Therapeutics, Inc. (JNCE) Report Negative Q1 Earnings? What You Should KnowWill Jounce Therapeutics, Inc. (JNCE) Report Negative Q1 Earnings? What You Should Know
finance.yahoo.com - May 1 at 5:10 PM
Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019
finance.yahoo.com - May 1 at 10:23 AM
Heres Why Jounce Therapeutics Rose 39.3% in MarchHere's Why Jounce Therapeutics Rose 39.3% in March
www.fool.com - April 9 at 10:20 PM
Here's Why Jounce Therapeutics Rose 39.3% in MarchHere's Why Jounce Therapeutics Rose 39.3% in March
finance.yahoo.com - April 9 at 10:20 PM
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual MeetingJounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 3 at 12:28 PM
Jounce up 8% on new vopratelimab dataJounce up 8% on new vopratelimab data
seekingalpha.com - April 2 at 6:51 PM
Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual MeetingJounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 2 at 1:49 PM
Investors Who Bought Jounce Therapeutics (NASDAQ:JNCE) Shares A Year Ago Are Now Down 80%Investors Who Bought Jounce Therapeutics (NASDAQ:JNCE) Shares A Year Ago Are Now Down 80%
finance.yahoo.com - March 12 at 9:04 PM
Edited Transcript of JNCE.O earnings conference call or presentation 6-Mar-19 1:00pm GMTEdited Transcript of JNCE.O earnings conference call or presentation 6-Mar-19 1:00pm GMT
finance.yahoo.com - March 8 at 10:46 AM
Jounce Therapeutics (JNCE) CEO Rich Murray on Q4 2018 Results - Earnings Call TranscriptJounce Therapeutics (JNCE) CEO Rich Murray on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 6 at 5:13 PM
Jounce Therapeutics Q4 top line up 55%Jounce Therapeutics Q4 top line up 55%
seekingalpha.com - March 6 at 10:35 AM
Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial ResultsJounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 6 at 10:35 AM
Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care ConferenceJounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
finance.yahoo.com - March 4 at 8:06 AM
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019
finance.yahoo.com - February 28 at 10:58 AM
Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual MeetingJounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - February 27 at 4:57 PM
Jounce Therapeutics Inc.Jounce Therapeutics Inc.
www.barrons.com - January 29 at 4:46 PM
Jounce Therapeutics (JNCE) Presents At 37th Annual J.P. Morgan Healthcare Conference - SlideshowJounce Therapeutics (JNCE) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 10 at 10:41 AM
Jounce advancing early-stage study of PD-1 inhibitor; shares up 2%Jounce advancing early-stage study of PD-1 inhibitor; shares up 2%
seekingalpha.com - January 3 at 4:43 PM
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
finance.yahoo.com - January 3 at 9:33 AM
Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare ConferenceJounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 9:11 AM
Hedge Funds Are Crazy About Jounce Therapeutics, Inc. (JNCE)Hedge Funds Are Crazy About Jounce Therapeutics, Inc. (JNCE)
finance.yahoo.com - December 23 at 8:50 AM
Report: Exploring Fundamental Drivers Behind Matrix Service, NantHealth, Earthstone Energy, Jounce Therapeutics, BeiGene, and Oxford Immunotec Global — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Matrix Service, NantHealth, Earthstone Energy, Jounce Therapeutics, BeiGene, and Oxford Immunotec Global — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - November 28 at 9:32 AM
Edited Transcript of JNCE.O earnings conference call or presentation 13-Nov-18 1:00pm GMTEdited Transcript of JNCE.O earnings conference call or presentation 13-Nov-18 1:00pm GMT
finance.yahoo.com - November 14 at 8:51 AM
Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q3 2018 Results - Earnings Call TranscriptJounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 13 at 4:45 PM
Jounce Therapeutics Q3 revenues down 20%Jounce Therapeutics Q3 revenues down 20%
seekingalpha.com - November 13 at 8:52 AM
Jounce Therapeutics Reports Third Quarter 2018 Financial ResultsJounce Therapeutics Reports Third Quarter 2018 Financial Results
finance.yahoo.com - November 13 at 8:52 AM
Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Tops Revenue EstimatesJounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 13 at 8:52 AM
Jounce Therapeutics Presents Reverse...Jounce Therapeutics Presents Reverse...
www.benzinga.com - November 10 at 4:45 PM
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual MeetingJounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
finance.yahoo.com - November 10 at 4:45 PM
Jounce Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 13, 2018Jounce Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 13, 2018
finance.yahoo.com - November 6 at 9:05 AM
Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for
www.zacks.com - November 5 at 10:37 AM
Jounce Therapeutics to Present Two Posters from the JTX-2011 Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual MeetingJounce Therapeutics to Present Two Posters from the JTX-2011 Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
finance.yahoo.com - November 2 at 4:51 PM
Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the ...Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the ...
www.nasdaq.com - October 1 at 4:40 PM
Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune RegulationJounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation
finance.yahoo.com - October 1 at 4:40 PM
Jounce Therapeutics to Present at the 2018 Cantor Global Healthcare ConferenceJounce Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
finance.yahoo.com - September 26 at 9:17 AM
Notable Tuesday Option Activity: HII, DAL, JNCENotable Tuesday Option Activity: HII, DAL, JNCE
www.nasdaq.com - September 4 at 4:40 PM
This page was last updated on 7/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel